Market Overview

US Stock Futures Signal Lower Start On Wall Street

US Stock Futures Signal Lower Start On Wall Street
Related UPS
Holiday Hiring: Jingling All The Way To Your Wallet
Baird Looking For UPS To Pull Back To The $95 Level
30 Trades To Profit From The Self-Driving Car (Seeking Alpha)
Related REGN
News Of Clinical Hold For Fasinumab Weighs On Regeneron, Teva Shares
Deal With Regeneron Means Validation For Ocular Therapeutix
Know This Sell Signal: When Stock Leaders Stage Big Downside Reversals (Investor's Business Daily)

Pre-open movers

US stock futures traded lower in early pre-market trade. The Markit PMI services index (flash) for January will be released at 9:45 a.m. ET, while the Dallas Fed general business activity index for January will be released at 10:30 a.m. ET. Futures for the Dow Jones Industrial Average tumbled 67 points to 17,521.00, while the Standard & Poor's 500 index futures fell 6.40 points to 2,037.50. Futures for the Nasdaq 100 index declined 7.25 points to 4,259.75.

A Peek Into Global Markets

European markets were mostly higher today, with the Spanish Ibex Index rising 0.25%, STOXX Europe 600 Index gaining 0.01% and German DAX 30 index rising 0.65%. French CAC 40 Index surged 0.01% and London's FTSE 100 Index fell 0.54%.

In Asian markets, Japan's Nikkei Stock Average fell 0.25%, Hong Kong's Hang Seng Index climbed 0.24% and China's Shanghai Composite Index jumped 0.94%. Japan's trade deficit shrank to Y660.7 billion in December.

Broker Recommendation
Analysts at Barclays downgraded United Parcel Service, Inc. (NYSE: UPS) from Overweight to Equal-weight. The price target for United Parcel Service has been lowered from $116 to $105.

United Parcel Service's shares closed at $102.93 on Friday.

Breaking news

  • Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NYSE: SNY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for PraluentTM (alirocumab). To read the full news, click here.
  • Shire plc (NASDAQ: SHPG) announces that the United States Food and Drug Administration has granted Fast Track designation for SHP609 (idursulfase-IT; also known as HGT-2310) for the treatment of neurocognitive decline associated with Hunter syndrome (mucopolysaccharidosis II or MPSII). To read the full news, click here.
  • Gilead Sciences (NASDAQ: GILD) today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. To read the full news, click here.
  • Rock-Tenn Company (NYSE: RKT) and MeadWestvaco Corporation (NYSE: MWV) today announced that they have entered into a definitive combination agreement to create a leading global provider of consumer and corrugated packaging ("NewCo") in a transaction with a combined equity value of $16 billion. To read the full news, click here.

Posted-In: Barclays US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets


Related Articles (GILD + MWV)

View Comments and Join the Discussion!